Among patients with prior or current exposure to lymphoma-directed therapies, 64% received an anti-CD20 mAb (28% receiving treatment <1 year prior to initial vaccination), 55% had prior cytotoxic chemotherapy, 15% were receiving Bruton tyrosine kinase inhibitors (BTKi), and 13% of patients were receiving Bcl-2 inhibitors (Bcl-2i). Here, BCL2 is linked to lymphoma.